Tektrotyd, 16 micrograms


Shelf life of the kit: 1 year
Labelled product must be stored at temperature below 25°C and used within 6 hours after preparation.


Store the kit in a refrigerator at 2°C - 8°C.
During transportation (not longer than 7 days) up to 35°C.
Expiry date is indicated on the package.
After labelling, store the medicinal product for no more than 6 hours at temperature below 25°C using appropriate radiation shielding. Storage of radiopharmaceuticals should be in accordance with national regulations on radioactive materials.

Pharmaceutical form: 

Kit for radiopharmaceutical preparation.
Lyophilisate for solution for injection.

Active substance: 

Vial I contains:
HYNIC-[D-Phe1,Tyr3-Octreotide]•TFA, 16 micrograms
The radionuclide is not part of the kit.


Vial I:
Tricine (N-[Tris(hydroxymethyl)methyl]glycine
Tin (II) chloride dihydrate
Vial II:
EDDA (ethylenediamine-N,N’-diacetic acid)
Disodium hydrogen phosphate dodecahydrate
Sodium hydroxide


The kit package contains two glass vials (Vial I and Vial II) of 10 ml volume, closed with a rubber stopper and an aluminium crimp cap. The vials are supplied in cardboard boxes. Vials I and II contain components for preparation of a radiopharmaceutical 99mTc-Tektrotyd.


99mTc-Tektrotyd, kit for radiopharmaceutical preparation is for diagnostic use only. 99mTc-Tektrotyd is a radiopharmaceutical indicated for diagnostics of pathological lesions in which  somatostatin receptors are overexpressed (particularly subtype 2 and, to a lesser extent, subtypes 3 and 5) and which may be imaged by the labelled ligand.
In particular, these are:
- gastro-entero-pancreatic neuroendocrine tumours (GEP-NET);
- pituitary adenomas;
- tumours originating in a sympathetic system; pheochromocytoma, paraganglioma, neuroblastoma, ganglioneurinoma etc.;
- medullary thyroid carcinoma;
- the preparation may be potentially useful in the case of other tumours expressing somatostatin receptors of various intensity. Other tumours which may overexpress somatostatin receptors: breast cancer, melanoma, lymphomas, prostate cancer, NSCLC, sarcoma, renal cell carcinoma, differentiated thyroid carcinoma, astrocytoma according to WHO I-IV (including glioblastoma multiforme G-M), meningiomas, ovarian cancer.




Our product range includes radiopharmaceuticals, radiochemicals, radioactivity standards and sealed radiation sources. We offer a broad selection of services and workshops, and training.

About Us

National Centre for Nuclear Research, Radioisotope Centre POLATOM is manufacturer and distributor of the isotopic goods applied in medicine, research and development, industry and environment protection.


The high professionalism of our company has been confirmed by a number of certificates including GMP for radiopharmaceutical production.